Xilio Therapeutics Insider Trades
NASDAQ: XLOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 1 · $43.95K
- Sales
- 2 · $5.70K
- Shares bought / sold
- 5.00K / 8.86K
- Net activity
- Net buying $38,254
Xilio Therapeutics insider activity
Over the last 12 months, Xilio Therapeutics insiders reported 7 transactions on SEC Form 4: 1 open-market purchase and 2 sales. Insiders bought $43,950 and sold $5,696 worth of stock, for net insider buying of $38,254. The largest seller was Frankenfield Christopher James, with $4,522 in reported sales.
The most recent filing shows Shannon James Samuel (Director) buying 5,000 shares at $8.79 on Mar 26, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put XLO's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
XLO insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Mar 26, 2026 | Shannon James SamuelDirector | Buy | 5,000 | $43.95K | Form 4 |
| Jan 2, 2026 | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Sale | 1,826 | $1.17K | Form 4 |
| Jan 2, 2026 | Frankenfield Christopher JamesChief Financial Officer | Sale | 7,030 | $4.52K | Form 4 |
| Jan 1, 2026 | Russo RenePRESIDENT AND CEO | Option exercise | 44,250 | — | Form 4 |
| Jan 1, 2026 | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Option exercise | 5,000 | — | Form 4 |
| Jan 1, 2026 | Luptakova KatarinaCHIEF MEDICAL OFFICER | Option exercise | 16,625 | — | Form 4 |
| Jan 1, 2026 | Frankenfield Christopher JamesChief Financial Officer | Option exercise | 19,375 | — | Form 4 |
| Jun 17, 2025 | Shannon James SamuelDirector | Buy | 25,000 | $17.21K | Form 4 |
| Jun 16, 2025 | Shannon James SamuelDirector | Buy | 45,000 | $30.87K | Form 4 |
| Jun 16, 2025 | Russo RenePRESIDENT AND CEO | Buy | 36,289 | $24.68K | Form 4 |
| Jan 2, 2025 | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Sale | 1,803 | $1.77K | Form 4 |
| Jan 2, 2025 | Frankenfield Christopher JamesChief Financial Officer | Sale | 6,954 | $6.84K | Form 4 |
| Jan 1, 2025 | Luptakova KatarinaCHIEF MEDICAL OFFICER | Option exercise | 16,625 | — | Form 4 |
| Jan 1, 2025 | Russo RenePRESIDENT AND CEO | Option exercise | 44,250 | — | Form 4 |
| Jan 1, 2025 | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Option exercise | 5,000 | — | Form 4 |
| Jan 1, 2025 | Frankenfield Christopher JamesChief Financial Officer | Option exercise | 19,375 | — | Form 4 |
| Dec 18, 2024 | GILEAD SCIENCES, INC.10% Owner | Buy | 1,759,978 | $1.83M | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4